Veda Zabih1, Alyssa Kahane2, Natalya E O'Neill3, Noah Ivers4,5, Paul C Nathan6,7. 1. Division of Hematology/Oncology, The Hospital for Sick Children, 555 University Avenue, Toronto, ON, M5G 1X8, Canada. 2. University of Ottawa, Ottawa, ON, Canada. 3. Faculty of Medicine, University of Toronto, Toronto, ON, Canada. 4. Department of Family and Community Medicine, University of Toronto, Toronto, ON, Canada. 5. Institute of Health Policy Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada. 6. Division of Hematology/Oncology, The Hospital for Sick Children, 555 University Avenue, Toronto, ON, M5G 1X8, Canada. paul.nathan@sickkids.ca. 7. Institute of Health Policy Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada. paul.nathan@sickkids.ca.
Abstract
PURPOSE: Many survivors of childhood cancer are at high risk of late effects of their cancer therapy, including cardiac toxicity and subsequent malignant neoplasms (SMN). Current North American guidelines recommend periodic surveillance for these late effects. We conducted a systematic review of the literature to estimate rates of adherence to recommended surveillance and summarize studies evaluating interventions intended to increase adherence. METHODS: We searched MEDLINE, Embase, Web of Science, and the Cumulative Index of Nursing and Allied Health Literature (CINAHL) for articles published between January 2000 and September 2018 that reported adherence to surveillance for cardiac toxicity and SMN (breast and colorectal cancer) and interventions implemented to improve completion of recommended testing. Risk of bias was assessed using relevant Cochrane checklists. Due to heterogeneity and overlapping study populations, we used narrative synthesis to summarize the findings. This review was registered in PROSPERO: CRD42018098878. RESULTS: Thirteen studies met our inclusion criteria for assessing adherence to surveillance, while five assessed interventions to improve rates of surveillance. No studies met criteria for low risk of bias. Completion of recommended surveillance was lowest for colorectal cancer screening (11.5-30.0%) followed by cardiomyopathy (22.3-48.1%) and breast cancer (37.0-56.5%). Factors such as patient-provider communication, engagement with the health care system, and receipt of information were consistently reported to be associated with higher rates of surveillance. Of five randomized controlled trials aimed at improving surveillance, only two significantly increase completion of recommended testing-one for echocardiography and one for mammography. Both involved telephone outreach to encourage and facilitate these tests. CONCLUSION: The majority of childhood cancer survivors at high risk of cardiac toxicity or SMN do not receive evidence-based surveillance. There is paucity of rigorous studies evaluating interventions to increase surveillance in this population. IMPLICATIONS FOR CANCER SURVIVORS: Robust trials are needed to assess whether tailored interventions, designed based on unique characteristics and needs of each survivor population, could improve adherence.
PURPOSE: Many survivors of childhood cancer are at high risk of late effects of their cancer therapy, including cardiac toxicity and subsequent malignant neoplasms (SMN). Current North American guidelines recommend periodic surveillance for these late effects. We conducted a systematic review of the literature to estimate rates of adherence to recommended surveillance and summarize studies evaluating interventions intended to increase adherence. METHODS: We searched MEDLINE, Embase, Web of Science, and the Cumulative Index of Nursing and Allied Health Literature (CINAHL) for articles published between January 2000 and September 2018 that reported adherence to surveillance for cardiac toxicity and SMN (breast and colorectal cancer) and interventions implemented to improve completion of recommended testing. Risk of bias was assessed using relevant Cochrane checklists. Due to heterogeneity and overlapping study populations, we used narrative synthesis to summarize the findings. This review was registered in PROSPERO: CRD42018098878. RESULTS: Thirteen studies met our inclusion criteria for assessing adherence to surveillance, while five assessed interventions to improve rates of surveillance. No studies met criteria for low risk of bias. Completion of recommended surveillance was lowest for colorectal cancer screening (11.5-30.0%) followed by cardiomyopathy (22.3-48.1%) and breast cancer (37.0-56.5%). Factors such as patient-provider communication, engagement with the health care system, and receipt of information were consistently reported to be associated with higher rates of surveillance. Of five randomized controlled trials aimed at improving surveillance, only two significantly increase completion of recommended testing-one for echocardiography and one for mammography. Both involved telephone outreach to encourage and facilitate these tests. CONCLUSION: The majority of childhood cancer survivors at high risk of cardiac toxicity or SMN do not receive evidence-based surveillance. There is paucity of rigorous studies evaluating interventions to increase surveillance in this population. IMPLICATIONS FOR CANCER SURVIVORS: Robust trials are needed to assess whether tailored interventions, designed based on unique characteristics and needs of each survivor population, could improve adherence.
Entities:
Keywords:
Childhood cancer; Late effects of cancer treatment; Screening; Survivorship
Authors: Paul Craig Nathan; Kirsten Kimberlie Ness; Martin Christopher Mahoney; Zhenghong Li; Melissa Maria Hudson; Jennifer Sylene Ford; Wendy Landier; Marilyn Stovall; Gregory Thomas Armstrong; Tara Olive Henderson; Leslie L Robison; Kevin Charles Oeffinger Journal: Ann Intern Med Date: 2010-10-05 Impact factor: 25.391
Authors: Annette E Maxwell; Roshan Bastani; Leda L Danao; Cynthia Antonio; Gabriel M Garcia; Catherine M Crespi Journal: Am J Public Health Date: 2010-09-23 Impact factor: 9.308
Authors: Kristin C Marr; Mohammad Agha; Rinku Sutradhar; Jason D Pole; David Hodgson; Astrid Guttmann; Mark Greenberg; Paul C Nathan Journal: J Cancer Surviv Date: 2017-08-07 Impact factor: 4.442
Authors: Katrin Hegenscheid; Wolfgang Hoffmann; Sebastian Fochler; Martin Domin; Stefan Weiss; Birgit Hartmann; Ulrich Bick; Norbert Hosten Journal: Am J Prev Med Date: 2011-10 Impact factor: 5.043
Authors: Paul C Nathan; Mohammad Agha; Jason D Pole; David Hodgson; Astrid Guttmann; Rinku Sutradhar; Mark L Greenberg Journal: J Cancer Surviv Date: 2016-02-11 Impact factor: 4.442
Authors: Alexandra M Psihogios; Yimei Li; Eliana Butler; Jessica Hamilton; Lauren C Daniel; Lamia P Barakat; Christopher P Bonafide; Lisa A Schwartz Journal: JMIR Mhealth Uhealth Date: 2019-04-18 Impact factor: 4.773
Authors: Stephanie B Dixon; Eric J Chow; Lars Hjorth; Melissa M Hudson; Leontien C M Kremer; Lindsay M Morton; Paul C Nathan; Kirsten K Ness; Kevin C Oeffinger; Gregory T Armstrong Journal: Pediatr Clin North Am Date: 2020-12 Impact factor: 3.278
Authors: Catherine Benedict; Jason Wang; Marina Reppucci; Charles L Schleien; Jonathan D Fish Journal: Transl Behav Med Date: 2021-02-11 Impact factor: 3.046
Authors: E Aleshchenko; E Swart; C Spix; M Voigt; P Trocchi; T Langer; G Calaminus; K Baust; J Glogner; P Ihle; J Küpper-Nybelen; C Lüpkes; T Kloppe; D Horenkamp-Sonntag; I Meier; U Marschall; P Dröge; M Klein; A Weiss; C Apfelbacher Journal: BMC Health Serv Res Date: 2022-09-20 Impact factor: 2.908